Evidence map›Paper›PMID 42016825›Full record

ArticleLiver cancer2026

Comparative Efficacy of Initial Treatment Strategies in Patients with Transarterial Chemoembolisation-Unsuitable Hepatocellular Carcinoma.

Edoardo G Giannini, Andrea Pasta, Giulia Pieri, Sara Labanca, Simona Marenco, Mario Strazzabosco, Mohamed Bouattour, Clémence Hollande, Antonio Facciorusso, Paolo Gallo and 29 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Liver cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

39 authors.

Edoardo G GianniniGastroenterology Unit, Department of Internal Medicine, University of Genoa, Genoa, Italy.
Andrea PastaGastroenterology Unit, Department of Internal Medicine, University of Genoa, Genoa, Italy.
Giulia PieriGastroenterology Unit, Department of Internal Medicine, University of Genoa, Genoa, Italy.
Sara LabancaGastroenterology Unit, Department of Internal Medicine, University of Genoa, Genoa, Italy.
Simona MarencoGastroenterology Unit, Department of Internal Medicine, University of Genoa, Genoa, Italy.
Mario StrazzaboscoLiver Center, Digestive Disease Section, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.
Mohamed BouattourLiver Cancer Unit, Hôpital Beaujon, Clichy, France.
Clémence HollandeLiver Cancer Unit, Hôpital Beaujon, Clichy, France.
Antonio FacciorussoGastroenterology Unit, Department of Experimental Medicine, Università del Salento, Lecce, Italy.
Paolo GalloClinical Medicine and Hepatology Unit, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy.
Ciro CelsaDepartment of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, PROMISE, Gastroenterology and Hepatology Unit, University of Palermo, Palermo, Italy.
Angelo SangiovanniDivision of Gastroenterology and Hepatology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Bernardo StefaniniDivision of Internal Medicine, Hepatobiliary Diseases and Immunoallergology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Claudia CampaniDepartment of Experimental and Clinical Medicine, Internal Medicine and Hepatology Unit, University of Florence, Florence, Italy.
Gabriele MissaleDepartment of Medicine and Surgery, Infectious Diseases and Hepatology Unit, University of Parma and Azienda Ospedaliero-Universitaria of Parma, Parma, Italy.
Gianpaolo VidiliDepartment of Medicine, Surgery and Pharmacy, Azienda Ospedaliero-Universitaria of Sassari, Sassari, Italy.
Giorgia GhittoniGastroenterology Unit, Santa Rosa Hospital, Viterbo, Italy.
Elisa PintoDepartment of Surgery, Oncology and Gastroenterology, Gastroenterology Unit, University of Padua, Padua, Italy.
Francesco Giuseppe FoschiDepartment of Internal Medicine, Ospedale per gli Infermi di Faenza, IRCCS IRST AUSL Romagna, Faenza, Italy.
Filomena MoriscoDepartment of Clinical Medicine and Surgery, Diseases of the Liver and Biliary System Unit, University of Naples "Federico II", Naples, Italy.
Giacomo ZaccheriniDepartment of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
Gianluca Svegliati-BaroniLiver Injury and Transplant Unit, Polytechnic University of Marche, Ancona, Italy.
Francesco AzzaroliDivision of Gastroenterology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Carlo SaittaDepartment of Clinical and Experimental Medicine, Clinical and Molecular Hepatology Unit, University of Messina, Messina, Italy.
Maurizia Rossana BrunettoDepartment of Clinical and Experimental Medicine, Hepatology and Liver Physiopathology Laboratory, University Hospital of Pisa, Pisa, Italy.
Rodolfo SaccoGastroenterology and Digestive Endoscopy Unit, Foggia University Hospital, Foggia, Italy.
Francesca Romana PonzianiLiver Unit, CEMAD - Centro Malattie dell'Apparato Digerente, Medicina Interna e Gastroenterologia, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario Gemelli IRCCS, Rome, Italy.
Sara BoninsegnaGastroenterology Unit, IRCCS Sacro Cuore Don Calabria Hospital, Negrar, Italy.
Gerardo NardoneDepartment of Clinical Medicine and Surgery, Hepato-Gastroenterology Unit, University of Naples "Federico II", Naples, Italy.
Andrea MartiniUnit of Internal Medicine and Hepatology, Department of Medicine, Azienda Ospedale Università Padova, Padova, Italy.
Andrea MegaGastroenterology Unit, Bolzano Regional Hospital, Bolzano, Italy.
David SacerdotiLiver Unit, Department of Medicine, University of Verona, Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy.
Donatella MagalottiRadiology Unit Fanti, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Maria Di MarcoMedicine Unit, Bolognini Hospital, Seriate, Italy.
Alessandro VitaleDepartment of Surgical, Oncological and Gastroenterological Sciences, University of Padova, Padova, Italy.
Laura BucciDepartment of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
Franco TrevisaniItalian Liver Cancer (ITA.LI.CA) Association, Bologna, Italy.
Italian Liver Cancer (ITA.LI.CA) Group
AIGO-CLEO Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Transarterial chemoembolisation (TACE) is considered the standard-of-care for patients with intermediate-stage hepatocellular carcinoma (HCC), despite several patients exhibit features that may be associated with suboptimal outcome of treatment - also referred to as TACE-unsuitable. In this study, our aim was to provide real-world evidence that patients who are considered TACE-unsuitable may receive greater benefit by systemic therapy than by TACE. Methods: This study analysed 1,150 patients with TACE-unsuitable HCC, defined according to Asia-Pacific Primary Liver Cancer Expert criteria. Patients were initially treated with TACE ( Results: Compared to TACE, atezolizumab/bevacizumab reduced mortality risk (hazard ratio [HR]: 0.47, 95% confidence interval [95% CI]: 0.27-0.80; Conclusions: In TACE-unsuitable patients, systemic treatment with atezolizumab/bevacizumab and, to a lesser extent, lenvatinib is associated with improved outcome compared to TACE. These findings support a paradigm shift in the initial management of intermediate-stage HCC, favouring the early use of systemic therapy in appropriately selected patients.

Indexed as

Atezolizumab/bevacizumabLocoregional treatmentOutcomeSystemic therapyTyrosine kinase inhibitors

Identifiers

PMID42016825
PMCPMC13095220

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.